Abstract
Gliomas, including glioblastoma which is the most lethal intracranial tumor, exhibit a very complex development that can lead to treatment resistance and recurrences. This heterogeneity can interfere in the diagnosis and, therefore, in the therapeutic approach. Currently, gliomas are classified based on histology and then graded on a scale of I to IV, depending on the degree of malignancy…